High Tumor Mutation Burden (TMB) and a Novel Somatic Mutation in the TREX1 Gene in a Patient with Aggressive and Refractory High-Grade B-Cell Lymphoma: A Case Report. [PDF]
Int J Mol SciGusakova M +11 more
europepmc +1 more source
Breaking barriers: harnessing hypofractionated radiotherapy to transform outcomes in low tumor mutation burden stage III non-small cell lung cancer - a retrospective study. [PDF]
Front ImmunolYang J +7 more
europepmc +1 more source
Tumor Mutation Burden Survey of AACR GENIE Database Revealed NTRK (NTRK+) and RET (RET+) Fusions Positive Colorectal Carcinoma (CRC) as Distinct Subsets. [PDF]
Cancer MedArter ZL, Lee ATM, Nagasaka M, Ou SI.
europepmc +1 more source
Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of BRAF Mutated (BRAF+) NSCLC. [PDF]
Lung Cancer (Auckl)Arter ZL, Shieh K, Nagasaka M, Ou SI.
europepmc +1 more source
Advanced gallbladder cancer with high tumor mutation burden: a case report and literature review. [PDF]
AME Case RepWang J +5 more
europepmc +1 more source
Tumor mutation burden and FAT3 mutation influence long-term survival in surgically resected small cell lung cancer. [PDF]
Transl Lung Cancer ResQian X, Zhu L, Han N, Qin J.
europepmc +1 more source
Utilizing multi-omics analysis, a new signature has been identified and validated for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma, which is based on tumor mutation burden. [PDF]
Discov OncolWang D, Wang Y, Peng Y, Peng L.
europepmc +1 more source
The baseline hemoglobin level is a positive biomarker for immunotherapy response and can improve the predictability of tumor mutation burden for immunotherapy response in cancer. [PDF]
Front PharmacolHe Y, Ren T, Ji C, Zhao L, Wang X.
europepmc +1 more source
Related searches:
Tumor Mutational Burden Testing in Solid Tumors
JAMA Oncology, 2023A 58-year-old man with diabetes, chronic kidney disease, and JAK2-positive myeloproliferative neoplasm is referred for newly diagnosed oligometastatic prostate cancer with substantial urinary symptoms. What would you do next?
Regina, Kwon +2 more
openaire +2 more sources
Tumor mutational burden and immunotherapy in gliomas
Trends in Cancer, 2021Tumor mutational burden (TMB) is an emerging biomarker for the prediction of immunotherapy success in solid tumors. Gliomas, however, do not demonstrate a correlation between TMB and immunotherapy efficacy. Here, we discuss the potential factors influencing this discordance, focusing on the impact of neoantigen immunogenicity, clonality, expression ...
Mythili Merchant +6 more
openaire +2 more sources